Page 126 - 2018_09-Mondo

J.F. San-Miguel et al.
multiple myeloma. Leukemia.
2006;20(9):1467-1473.
32. Mateos MV, Oriol A, Martinez-Lopez J, et
al. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long- term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016;95(12):2033-2041.
33. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, mel- phalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518- 528.
34. Jagannath S, Roy A, Kish J, et al. Real-world treatment patterns and associated progres- sion-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016;9(7):707-717.
35. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treat- ment for multiple myeloma. Blood. 2018; 131(3):301-310.
36. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexam- ethasone versus lenalidomide and dexam- ethasone alone in patients with newly diag-
nosed myeloma without intent for immedi- ate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-527.
37. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus mel- phalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832-3842.
41. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014; 124(7):1038-1046.
42. Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexam- ethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017;178(4):571-
38. Facon T, Mary JY, Hulin C, et al. Melphalan 582.
and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a ran- domised trial. Lancet. 2007;370(9594):1209- 1218.
39. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalido- mide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664- 3670.
40. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014; 124(7):1047-1055.
43. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.
44. Gupta N, Yang H, Hanley MJ, et al. Dose and schedule selection of the oral protea- some inhibitor ixazomib in relapsed/refrac- tory multiple myeloma: clinical and model- based analyses. Target Oncol. 2017; 12(5):643-654.
45. Gupta N, Diderichsen PM, Hanley MJ, et al. Population pharmacokinetic analysis of ixa- zomib, an oral proteasome inhibitor, includ- ing data from the phase III TOURMALINE- MM1 study to inform labelling. Clin Pharmacokinet. 2017;56(11):1355-1368.
1526
haematologica | 2018; 103(9)